TY - JOUR
T1 - PET imaging of primary mediastinal tumours
AU - Kubota, K.
AU - Yamada, S.
AU - Kondo, T.
AU - Yamada, K.
AU - Fukuda, H.
AU - Fujiwara, T.
AU - Ito, M.
AU - Ido, T.
N1 - Funding Information:
The authors thank Mr Sugawara for photography, Mr Watanuki and Mr Seo for PET operation and Professor H Orihara, and the staff of the Cyclotron and Radioisotope Center, Tohoku Uni- versity, for their assistance. We also thank Dr FG Issa (Word- Medex) for his assistance in reading and editing the manuscript. This work was supported by grants-in-aid (06454320, 06670899, 07274206) from the Ministry of Education, Science and Culture, Japan.
PY - 1996
Y1 - 1996
N2 - Mediastinal masses include a wide variety of tumours and remain an interesting diagnostic challenge for radiologists. We performed positron emission tomography (PET) studies of primary mediastinal tumours in order to predict the malignancy of these tumours preoperatively. Twenty-two patients with primary mediastinal tumours were studied with PET using 2-deoxy-2-[18F]fluoro-D-glucose (FDG). The histological findings of surgical pathology or biopsy, or mediastinoscopy were compared with those of computerised tomography (CT) and PET. PET images were evaluated semiquantitatively using the differential uptake ratio (DUR). Increased FDG uptake was observed in nine of ten patients with malignant tumours, including thymic carcinomas, lymphomas, invasive thymomas and a case of sarcoidosis. A moderate level of FDG uptake was found in a myeloma, non-invasive thymomas, and a schwannoma, whereas a low uptake was observed in a teratoma and various benign cysts. The mean FDG uptake of malignant tumours was significantly higher than that of benign tumours. Both thymic cancer and invasive thymoma showed a high FDG uptake, whereas noninvasive thymoma and other benign tumours showed a low FDG uptake. CT examination resulted in three false-negative and two false-positive cases when used in predicting tumour invasion, while PET was associated with a false-positive and a false-negative case. In conclusion, the use of FDG with PET is clinically helpful in evaluating the malignant nature of primary mediastinal tumours. Our results also suggest that a high FDG uptake reflects the invasiveness or malignant nature of thymic tumours.
AB - Mediastinal masses include a wide variety of tumours and remain an interesting diagnostic challenge for radiologists. We performed positron emission tomography (PET) studies of primary mediastinal tumours in order to predict the malignancy of these tumours preoperatively. Twenty-two patients with primary mediastinal tumours were studied with PET using 2-deoxy-2-[18F]fluoro-D-glucose (FDG). The histological findings of surgical pathology or biopsy, or mediastinoscopy were compared with those of computerised tomography (CT) and PET. PET images were evaluated semiquantitatively using the differential uptake ratio (DUR). Increased FDG uptake was observed in nine of ten patients with malignant tumours, including thymic carcinomas, lymphomas, invasive thymomas and a case of sarcoidosis. A moderate level of FDG uptake was found in a myeloma, non-invasive thymomas, and a schwannoma, whereas a low uptake was observed in a teratoma and various benign cysts. The mean FDG uptake of malignant tumours was significantly higher than that of benign tumours. Both thymic cancer and invasive thymoma showed a high FDG uptake, whereas noninvasive thymoma and other benign tumours showed a low FDG uptake. CT examination resulted in three false-negative and two false-positive cases when used in predicting tumour invasion, while PET was associated with a false-positive and a false-negative case. In conclusion, the use of FDG with PET is clinically helpful in evaluating the malignant nature of primary mediastinal tumours. Our results also suggest that a high FDG uptake reflects the invasiveness or malignant nature of thymic tumours.
KW - Mediastinal tumour
KW - Positron emission tomography
KW - Thymoma
KW - [F]fluorodeoxyglucose
UR - http://www.scopus.com/inward/record.url?scp=0029924606&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029924606&partnerID=8YFLogxK
U2 - 10.1038/bjc.1996.157
DO - 10.1038/bjc.1996.157
M3 - Article
C2 - 8611400
AN - SCOPUS:0029924606
SN - 0007-0920
VL - 73
SP - 882
EP - 886
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 7
ER -